Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Arcturus Therapeutics Holdings Inc.

Get SEC filing alerts via email and in your feed for Arcturus Therapeutics Holdings Inc.

ARCT

Arcturus Therapeutics Holdings Inc.

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc. develops mRNA-based medicines, focusing on infectious disease vaccines and rare genetic disorders. Its proprietary self-amplifying mRNA (STARR) and lipid nanoparticle delivery (LUNAR) platforms enable low-dose, durable immune responses and targeted therapeutic protein expression. The company’s portfolio includes COVID-19 and influenza vaccines and treatments for ornithine transcarbamylase deficiency and cystic fibrosis, serving global healthcare markets through partnerships and scalable manufacturing.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Arcturus Therapeutics Holdings Inc.

1
1
Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Reports 93% Revenue Decline and Increased Net Loss in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Reports 46% Revenue Decline and $74.3 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Reports 59% Revenue Decline and Increased Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Reports 43% Revenue Decline in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Reports $29.4 Million Revenue in Q1 2025, Down 23% Year-Over-Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Reports $152.3M Revenue Decline and $80.9M Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Reports Decline in Revenue and Increased Net Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments